Document Detail

Serum tumor necrosis factor for monitoring response of hepatic veno-occlusive disease to pentoxiphyllin--a case report.
MedLine Citation:
PMID:  9246154     Owner:  NLM     Status:  MEDLINE    
Hepatic veno-occlusive disease (VOD) is the second most common cause of death after autologous bone marrow transplantation (ABMT). A patient with multiple myeloma undergoing ABMT developed classic features of hepatic VOD. He responded to treatment with pentoxiphyllin. Serum tumor necrosis factor (TNF) levels showed remarkable correlation with the severity of VOD and response to therapy.
P M Parikh; S H Advani; J S Nadkarni; S Kulkarni; G Kapoor; P S Sastry; M Anand; T K Saikia; R Gopal
Related Documents :
21271294 - Free terminal time optimal control problem of an hiv model based on a conjugate gradi...
21301944 - Routine prenatal hiv testing: women's concerns and their strategies for addressing conc...
21350364 - Predictors of survival after a diagnosis of non-hodgkin lymphoma in a resource-limited ...
21355514 - An analysis of three opportunistic infections in an outpatient hiv clinic in jamaica.
12958224 - Importance of methodology in determination of chlamydia pneumoniae seropositivity in he...
11129354 - Infant birth weight among women with or at high risk for hiv infection: the impact of c...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Cancer investigation     Volume:  15     ISSN:  0735-7907     ISO Abbreviation:  Cancer Invest.     Publication Date:  1997  
Date Detail:
Created Date:  1997-08-25     Completed Date:  1997-08-25     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8307154     Medline TA:  Cancer Invest     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  326-8     Citation Subset:  IM    
Department of Medical Oncology, Tata Memorial Hospital Parel, Mumbai, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Marrow Transplantation / adverse effects
Dopamine / therapeutic use
Hepatic Veno-Occlusive Disease / blood*,  drug therapy*,  etiology
Multiple Myeloma / surgery
Pentoxifylline / therapeutic use*
Spironolactone / therapeutic use
Tumor Necrosis Factor-alpha / analysis*
Vasodilator Agents / therapeutic use*
Reg. No./Substance:
0/Tumor Necrosis Factor-alpha; 0/Vasodilator Agents; 52-01-7/Spironolactone; 6493-05-6/Pentoxifylline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phase II trial of topotecan in malignant melanoma.
Next Document:  The biological therapy of acute and chronic leukemia.